Condensed Consolidating Financial Statements (Details 4) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Sources (uses) of cash and cash equivalents
Net cash provided by (used in) operating activities	$ (3,270)	$ (26,312)
Investing activities:
Capital expenditures	(17,474)	(24,993)
Change in restricted cash	11,509	3,532
Proceeds from sale of assets	4,540	0
Proceeds from sale of discontinued operations	9,564	0
Net cash provided by (used in) investing activities	8,139	(21,461)
Financing activities:
Proceeds from revolving line of credit	42,340	21,000
Payments of revolving line credit	(14,342)	0
Deferred acquisition payments	(11,899)	(11,703)
Payments on long-term debt	(21,733)	(2,858)
Proceeds from exercise of stock options	24	86
Net cash provided by (used in) financing activities	(5,610)	6,525
Net increase (decrease) in cash and cash equivalents	(741)	(41,248)
Effect of foreign currency fluctuations on cash	(1,606)	864
Cash and cash equivalents at beginning of fiscal period	57,929	95,978
Cash and cash equivalents at end of fiscal period	55,582	55,594
Reportable legal entities | Parent
Sources (uses) of cash and cash equivalents
Net cash provided by (used in) operating activities	31,316	(3,339)
Investing activities:
Capital expenditures	0	0
Change in restricted cash	0	0
Proceeds from sale of assets	0
Proceeds from sale of discontinued operations	0
Net cash provided by (used in) investing activities	0	0
Financing activities:
Proceeds from revolving line of credit	0	0
Payments of revolving line credit	0
Deferred acquisition payments	(10,899)	(10,703)
Payments on long-term debt	(20,417)	(2,841)
Proceeds from exercise of stock options	24	86
Net cash provided by (used in) financing activities	(31,292)	(13,458)
Net increase (decrease) in cash and cash equivalents	24	(16,797)
Effect of foreign currency fluctuations on cash	0	0
Cash and cash equivalents at beginning of fiscal period	616	17,202
Cash and cash equivalents at end of fiscal period	640	405
Reportable legal entities | Guarantor Subsidiaries
Sources (uses) of cash and cash equivalents
Net cash provided by (used in) operating activities	(18,502)	(30,386)
Investing activities:
Capital expenditures	(9,542)	(10,955)
Change in restricted cash	11,509	3,532
Proceeds from sale of assets	2,274
Proceeds from sale of discontinued operations	0
Net cash provided by (used in) investing activities	4,241	(7,423)
Financing activities:
Proceeds from revolving line of credit	37,340	9,000
Payments of revolving line credit	(14,342)
Deferred acquisition payments	(1,000)	(1,000)
Payments on long-term debt	0	(17)
Proceeds from exercise of stock options	0	0
Net cash provided by (used in) financing activities	21,998	7,983
Net increase (decrease) in cash and cash equivalents	7,737	(29,826)
Effect of foreign currency fluctuations on cash	(1)	(672)
Cash and cash equivalents at beginning of fiscal period	22,200	52,056
Cash and cash equivalents at end of fiscal period	29,936	21,558
Reportable legal entities | Non-Guarantor Subsidiaries
Sources (uses) of cash and cash equivalents
Net cash provided by (used in) operating activities	(16,084)	7,413
Investing activities:
Capital expenditures	(7,932)	(14,038)
Change in restricted cash	0
Proceeds from sale of assets	2,266
Proceeds from sale of discontinued operations	9,564
Net cash provided by (used in) investing activities	3,898	(14,038)
Financing activities:
Proceeds from revolving line of credit	5,000	12,000
Payments of revolving line credit	0
Deferred acquisition payments	0	0
Payments on long-term debt	(1,316)	0
Proceeds from exercise of stock options	0	0
Net cash provided by (used in) financing activities	3,684	12,000
Net increase (decrease) in cash and cash equivalents	(8,502)	5,375
Effect of foreign currency fluctuations on cash	(1,605)	1,536
Cash and cash equivalents at beginning of fiscal period	35,113	26,720
Cash and cash equivalents at end of fiscal period	25,006	33,631
Reclassifications and Eliminations
Sources (uses) of cash and cash equivalents
Net cash provided by (used in) operating activities	0	0
Investing activities:
Capital expenditures	0	0
Change in restricted cash	0	0
Proceeds from sale of assets	0
Proceeds from sale of discontinued operations	0
Net cash provided by (used in) investing activities	0	0
Financing activities:
Proceeds from revolving line of credit	0	0
Payments of revolving line credit	0
Deferred acquisition payments	0	0
Payments on long-term debt	0	0
Proceeds from exercise of stock options	0	0
Net cash provided by (used in) financing activities	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Effect of foreign currency fluctuations on cash	0	0
Cash and cash equivalents at beginning of fiscal period	0	0
Cash and cash equivalents at end of fiscal period	$ 0	$ 0